Please login to the form below

Not currently logged in
Email:
Password:

Ra Pharma

This page shows the latest Ra Pharma news and features for those working in and with pharma, biotech and healthcare.

Roche wins early use RA approval for RoActemra in Europe

Roche wins early use RA approval for RoActemra in Europe

for patients with early RA that may change the course of disease and reduce the likelihood of disability. ... The anti-TNFs are currently the three biggest-selling pharma products in the world with combined revenues last year of around $30bn.

Latest news

  • Positive results in Sanofi RA trial

    According to Sanofi, the MOBILITY study, involving 306 participants, demonstrated that patients treated with sarilumab in combination with a standard RA treatment, methotrexate (MTX), achieved a significant improvement in signs and ... symptoms of

  • NICE recommends RA drug

    The UK's National Institute for Health and Clinical Excellence (NICE) has issued final guidance recommending Centocor Ortho Biotech's rheumatoid arthritis (RA) drug Simponi (golimumab) for use on the NHS ... The drug is recommended for adults with severe

  • AZ's phase III RA trial underway

    AstraZeneca (AZ) has announced the beginning of phase III clinical trial development for rheumatoid arthritis (RA) treatment fostamatinib. ... Syk is a form of tyrosine kinase protein that can lead to the inflammatory conditions of RA when functioning

  • Galapagos acquires GSK RA compound rights

    Belgium's Galapagos has acquired the full rights to an investigational arthritis compound from GSK and is commencing a phase I clinical trial - PMLiVE

  • Pfizer scraps RA drug

    Pfizer has decided to scrap development of a drug for a very large market – rheumatoid arthritis (RA). ... Trubion noted that Pfizer intends to continue development of another RA product that is part of the collaboration, SBI-087.

More from news
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch table for April 2013 Deal Watch table for April 2013

    For an indepth analysis of these deals, read'Pharma deals during April 2013'. ... 210+. Ra Pharma/ Merck &Co. Collaboration. Extreme Diversity platform to develop Cyclomimetic candidates for protein targets in multiple therapeutic areas.

  • An eye towards the biobetter in South Korea An eye towards the biobetter in South Korea

    Humira (Adalimumab). unknown. Dong-A Pharma. Meiji Seika Pharma. RA. S Korea. ... This decreased profit margins of domestic pharma manufacturers by an average of 3.4 per cent. .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....

Infographics